Amgen, J&J Revise Labels For Aranesp, Epogen, Procrit
This article was originally published in The Pink Sheet Daily
Executive Summary
Amgen says it will present new data to CMS in effort to persuade agency to modify its National Coverage Decision on ESAs.
You may also be interested in...
J&J’s R&D Spending To Ease As Firm Focuses On Taking Pipeline To Market
Firm reports slight sales growth as generics and a constricting ESA market take their toll on current products.
J&J’s R&D Spending To Ease As Firm Focuses On Taking Pipeline To Market
Firm reports slight sales growth as generics and a constricting ESA market take their toll on current products.
European Regulators Approve Labeling Update For Amgen’s Aranesp
Revised European ESA prescribing information consistent with proposal released last fall.